Fig. 4.

Effects of 15d-PGJ₂ on the anti-cancerous activities of topoisomerase inhibitors in ACHN cells. ACHN cells were treated with CPT (A), VP-16 (B), DOX (C) or 15d-PGJ₂ (D) at the indicated concentrations for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 3). *P < 0.05, compared with control, **P < 0.01, compared with control. (E) ACHN cells were treated with 0.5 μM CPT, 50 μM VP-16 or 0.5 μM DOX in the absence (open column) or presence (closed column) of 30 μM 15d-PGJ₂ for 24 h. Cell viabilities were determined by MTT-reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. ^##P < 0.01, compared with each topoisomerase inhibitor alone. (F) ACHN cells were treated with 0.5 μM CPT, 50 μM VP-16 or 0.5 μM DOX in the absence or presence of 30 μM 15d-PGJ₂ for 24 h. Morphologies were photographed by phase contrast. Scale bar = 100 µm.